肌脂肪变性对胰腺癌患者生存的影响：一项系统评价与荟萃分析。
Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis.
作者信息
Zhang Xin, Wei Licheng, Li Jiangguo, Deng Yuexia, Xu Wei, Chen Dongkui, Li Xing
机构信息
Department of Gastroenterology, The Fourth Hospital of Changsha, Changsha City, Hunan Province 410006, P.R. China.
Department of Critical Care Medicine, Changsha Hospital of Traditional Chinese Medicine (Changsha No. 8 Hospital), Changsha City, Hunan Province 410100, P.R. China.
出版信息
iScience. 2024 Nov 7;27(12):111343. doi: 10.1016/j.isci.2024.111343. eCollection 2024 Dec 20.
The present meta-analysis aims to evaluate the impact of myosteatosis on overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer (PC). A comprehensive literature search was conducted in the Medline, Web of Science, and Embase databases. The hazard ratio (HR) and corresponding 95% confidence interval (CI) for the association between myosteatosis and survival outcomes were pooled using a random-effects model. A total of 14 studies were included. The pooled analysis demonstrated that myosteatosis was significantly associated to poorer OS (HR: 1.50, 95% CI: 1.35-1.67, < 0.001; = 0%). The subgroup analysis revealed consistent results across various study characteristics, including geographic regions, cancer stages, follow-up durations, and study quality. In addition, myosteatosis was associated to worse PFS (HR: 1.34, 95% CI: 1.15-1.57, < 0.001; = 34%). The present meta-analysis indicates that myosteatosis is associated to significantly worse OS and PFS in patients with PC.
本荟萃分析旨在评估肌脂肪变性对胰腺癌（PC）患者总生存期（OS）和无进展生存期（PFS）的影响。在Medline、科学网和Embase数据库中进行了全面的文献检索。使用随机效应模型汇总肌脂肪变性与生存结果之间关联的风险比（HR）及相应的95%置信区间（CI）。共纳入14项研究。汇总分析表明，肌脂肪变性与较差的OS显著相关（HR：1.50，95%CI：1.35 - 1.67，<0.001；I² = 0%）。亚组分析显示，在包括地理区域、癌症分期、随访时间和研究质量等各种研究特征中，结果一致。此外，肌脂肪变性与较差的PFS相关（HR：1.34，95%CI：1.15 - 1.57，<0.001；I² = 34%）。本荟萃分析表明，肌脂肪变性与PC患者显著更差的OS和PFS相关。
Zotero 插件